Dimethyl fumarate is an oral medication used to treat relapsing forms of multiple sclerosis (MS) in adults. Sold under the brand name Tecfidera, it was first approved by the FDA in 2013 and works by reducing inflammation and protecting nerve cells from damage. It belongs to a class of drugs called Nrf2 activators, which help the body defend against the oxidative stress that contributes to MS progression.
How It Works in the Body
Dimethyl fumarate operates through several pathways at once. Its primary mechanism involves switching on a protective system inside cells called the Nrf2 pathway. When activated, this pathway ramps up the production of proteins that neutralize harmful molecules and reduce oxidative damage to nerve tissue. Think of it as turning up the body’s built-in antioxidant defense system.
Beyond that antioxidant role, the drug also reshapes the immune system in ways that reduce MS activity. It lowers the production of inflammatory signaling molecules, makes it harder for aggressive immune cells to cross from the bloodstream into the brain, and shifts the overall balance of immune cells toward a less inflammatory profile. Studies in MS patients show that treatment leads to fewer circulating immune cells associated with attacks on nerve tissue, while boosting a type of natural killer cell linked to immune regulation.
Interestingly, animal research has shown that dimethyl fumarate still provides benefits even when the Nrf2 pathway is completely knocked out, suggesting it also works through at least one alternative route involving a receptor called HCAR2. This multi-pronged action likely explains why it performs well in clinical trials.
What It Treats
The FDA-approved indication covers relapsing forms of MS in adults. That umbrella includes three specific patterns of the disease: clinically isolated syndrome (a first episode of neurological symptoms lasting at least 24 hours), relapsing-remitting MS (the most common form, where symptoms flare and then partially or fully resolve), and active secondary progressive MS (a later stage where relapses still occur alongside gradual worsening).
In two large phase III clinical trials, dimethyl fumarate reduced the annual relapse rate by 44% to 53% compared to placebo. It also cut the number of new brain lesions visible on MRI by 71% to 90%. Both results were statistically significant, placing it among the more effective oral MS therapies available.
Dosing and How It’s Taken
Dimethyl fumarate comes as a delayed-release capsule taken by mouth twice a day. Treatment starts at a lower dose of 120 mg twice daily for the first seven days, then increases to the full maintenance dose of 240 mg twice daily. This gradual ramp-up helps the body adjust and reduces early side effects, particularly stomach-related ones.
Common Side Effects
The two side effects patients notice most are flushing and gastrointestinal symptoms. Flushing typically involves warmth, redness, or a tingling sensation in the skin, similar to what people experience with niacin supplements. It tends to be most noticeable in the first few weeks and generally fades over time.
Stomach-related symptoms are even more common. In one open-label study, about 88% of patients reported at least one GI event over 12 weeks. Nausea affected roughly 63% of patients, flatulence about 70%, and constipation around 42%. Vomiting was less frequent, occurring in about 17% of patients. These numbers sound high, but for most people the symptoms are manageable and improve as the body adjusts to the medication.
Taking the capsules with food is one of the simplest ways to ease both flushing and stomach upset. An international panel of clinicians has also found that low-dose aspirin taken before the medication helps reduce flushing during the first few months of therapy. Adjusting the timing of doses throughout the day can help as well.
Blood Monitoring and Rare Risks
Dimethyl fumarate can lower lymphocyte counts, a type of white blood cell critical for fighting infections. Because of this, a complete blood count is required before starting treatment, and blood tests should be repeated every three months while on the drug. If lymphocyte levels drop below a certain threshold and stay low for more than six months, doctors need to reassess whether continuing treatment makes sense.
The reason this monitoring matters is a rare but serious brain infection called progressive multifocal leukoencephalopathy (PML). PML is caused by the JC virus, which most people carry without problems. But when the immune system is significantly weakened, particularly when lymphocyte counts remain very low for an extended period, the virus can reactivate and cause progressive neurological damage. As of the European Medicines Agency’s safety review, three confirmed cases of PML had occurred in patients on dimethyl fumarate who had prolonged severe lymphocyte suppression lasting more than six months. The risk remains very low overall, but consistent blood monitoring is the main safeguard.
Its Other Identity as an Industrial Chemical
Outside of medicine, dimethyl fumarate has an entirely different reputation. Manufacturers in some countries used it as an anti-mold agent, placing small sachets of the chemical inside furniture, shoes, and other leather goods to prevent mold growth during shipping and storage in humid conditions. The chemical would evaporate from the sachets and saturate the leather.
The problem emerged when consumers in several European countries developed severe skin reactions after contact with treated products. The chemical penetrated through clothing and caused painful dermatitis, including itching, burns, redness, and in some cases acute breathing difficulties. Hundreds of consumers were affected. While the EU had already banned the use of dimethyl fumarate as a biocide in domestic manufacturing, imported goods from countries without such restrictions were still reaching European markets. The EU moved to ban dimethyl fumarate in all consumer products, closing that gap and applying the same protection to imports.
The concentrations and formulations used in consumer goods are entirely different from the pharmaceutical version. The medical product is a precisely dosed, delayed-release capsule designed to be processed through the digestive system, not absorbed through the skin at uncontrolled levels.